InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,399.22
(
-0.51%
)
US TECH 100
18,362.00
(
-0.93%
)
Dow Jones
39,935.07
(
0.20%
)
Brent Oil
81.70
(
0.20%
)
Bitcoin
66,354.35
(
0.86%
)
Post# of 252682
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120121
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ThomasS post# 30726

Tuesday, 08/08/2006 11:19:59 PM

Tuesday, August 08, 2006 11:19:59 PM

Post# of 252682
ANDS CC notes:

1. ANA380 for HBV:
a) The period during which NVS had the exclusive right to license ANA380 has expired. NVS could conceivably still license the drug, but it’s less likely because they no longer have any special standing relative to other bidders.
b) The design of phase-3 will be determined by observing six-month data from the not yet started phase-2b trial. The most likely design of phase-3 is to test the 90mg and 150mg doses in Lamivudine-refractory patients.

2. ANA975 for HBV: Due to the animal tox issues disclosed in late June, there will be no IND in 2006 for the HBV indication as was previously planned. (The FDA has placed a hold on the ANA975 program in HCV.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up